Spil Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPIL
SPIL has five approved drugs.
There are five US patents protecting SPIL drugs.
There are ten patent family members on SPIL drugs in eight countries and nine supplementary protection certificates in four countries.
Summary for Spil
| International Patents: | 10 |
| US Patents: | 5 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-001 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-002 | Jan 26, 2018 | RX | Yes | No | 9,700,530 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-001 | Feb 28, 2022 | DISCN | Yes | No | 11,510,878 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | ASPRUZYO SPRINKLE | ranolazine | GRANULE, EXTENDED RELEASE;ORAL | 216018-002 | Feb 28, 2022 | DISCN | Yes | No | 12,161,761 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-003 | Jan 26, 2018 | RX | Yes | No | 9,504,655 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | AMPHOTERICIN B | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 212514-001 | Dec 14, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2015287299 | ⤷ Start Trial |
| Brazil | 112017000468 | ⤷ Start Trial |
| Japan | 2017523164 | ⤷ Start Trial |
| Japan | 6626492 | ⤷ Start Trial |
| European Patent Office | 4578510 | ⤷ Start Trial |
| Canada | 2954474 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1109558 | 09C0001 | France | ⤷ Start Trial | PRODUCT NAME: RANOLAZINE; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714 |
| 1411900 | 2011/016 | Ireland | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1411900 | 2011C/016 | Belgium | ⤷ Start Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| 1411900 | SPC/GB11/015 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
